A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

J Peng, M Fan, C An, F Ni, W Huang… - Basic & clinical …, 2022 - Wiley Online Library
Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …

Cannabis pharmacology: the usual suspects and a few promising leads

EB Russo, J Marcu - Advances in pharmacology, 2017 - Elsevier
The golden age of cannabis pharmacology began in the 1960s as Raphael Mechoulam and
his colleagues in Israel isolated and synthesized cannabidiol, tetrahydrocannabinol, and …

Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain

D De Gregorio, RJ McLaughlin, L Posa… - Pain, 2019 - journals.lww.com
Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of
cannabis that interacts with the serotonin (5-HT) 1A receptor, may possess analgesic and …

Cannabidiol, neuroprotection and neuropsychiatric disorders

AC Campos, MV Fogaça, AB Sonego… - Pharmacological …, 2016 - Elsevier
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis
sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders …

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

S Bonaccorso, A Ricciardi, C Zangani, S Chiappini… - Neurotoxicology, 2019 - Elsevier
Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …

[HTML][HTML] Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders

N Masataka - Frontiers in psychology, 2019 - frontiersin.org
Accumulated evidence indicates that cannabidiol (CBD), a nonpsychotomimetic and
nonaddictive main component of the Cannabis sativa plant, reverses anxiety-like behavior …

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

DL Boggs, T Surti, A Gupta, S Gupta, M Niciu… - …, 2018 - Springer
Rationale Preliminary evidence suggests that cannabidiol (CBD) may be effective in the
treatment of neurodegenerative disorders; however, CBD has never been evaluated for the …

Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement

G Esposito, C Scuderi, M Valenza, GI Togna, V Latina… - PloS one, 2011 - journals.plos.org
Peroxisome proliferator-activated receptor-γ (PPARγ) has been reported to be involved in
the etiology of pathological features of Alzheimer's disease (AD). Cannabidiol (CBD), a …

Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease

A Vallée, Y Lecarpentier, R Guillevin… - Acta biochimica et …, 2017 - academic.oup.com
Alzheimer's disease (AD) is a neurodegenerative disease, in which the primary etiology
remains unknown. AD presents amyloid beta (Aβ) protein aggregation and neurofibrillary …

Does cannabidiol protect against adverse psychological effects of THC?

RJM Niesink, MW van Laar - Frontiers in psychiatry, 2013 - frontiersin.org
The recreational use of cannabis can have persistent adverse effects on mental health.
Delta-9-tetrahydrocannabinol (THC) is the main psychoactive constituent of cannabis, and …